FDA Guidance for Industry Changes to an Approved NDA or ANDA

该指南第7章

Major Changes (prior Approval Supplement)

Changes that may affect drug product sterility assurance including, where appropriate, process changes for sterile drug substances and sterile packaging components.

Changes to aseptic processing methods, including scale, that extend the total processing, including bulk storage time, by more than 50 percent beyond the validated limits in the approved application.